SGLT-2 inhibitors have revolutionized the management of chronic diseases, demonstrating profound cardiovascular and renal protective effects that extend beyond their original purpose of glucose-lowering in T2DM. These agents target fundamental pathophysiological mechanisms, including hemodynamic regulation, metabolic efficiency, inflammation, and oxidative stress, making them effective across diverse populations. Landmark clinical trials such as EMPA-REG OUTCOME, CANVAS, DAPA-HF, and DAPA-CKD have shown significant reductions in cardiovascular death, heart failure hospitalizations, and the progression of CKD, even in non-diabetic patients. While generally well-tolerated, SGLT-2 inhibitors require careful patient selection to mitigate risks such as euglycemic diabetic ketoacidosis and volume depletion. Their broad applicability underscores their role as a cornerstone therapy, redefining integrated care for heart failure, CKD, and related conditions. As research expands, SGLT-2 inhibitors promise to further transform chronic disease management, offering improved outcomes, quality of life, and survival for millions worldwide.
No takes yet. Share an insight, caveat, or question.
Lidong Wang (2025) studied this question.